{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:23:45Z","timestamp":1793291025577,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Nephrotic proteinuria is the hallmark of several glomerulonephritis determined by different pathogenetic mechanisms, including autoimmune, degenerative and inflammatory. Some conditions such as Minimal Change Nephropathy (MCN) and Focal Segmental Glomerulosclerosis (FSGS) are of uncertain pathogenesis. Chimeric anti-CD20 monoclonal antibodies have been used with success in a part of proteinuric conditions while some are resistant. New human and humanized monoclonal anti-CD 20 antibodies offer some advantages based on stronger effects on CD20 cell subtypes and have been already administered in hematology and oncology areas as substitutes of chimeric molecules. Here, we revised the literature on the use of human and humanized anti-CD 20 monoclonal antibodies in different proteinuric conditions, resulting effective in those conditions resistant to rituximab. Literature on the use of human anti-CD 20 monoclonal antibodies in different proteinuric diseases is mainly limited to ofatumumab, with several protocols and doses. Studies already performed with ofatumumab given in standard doses of 1,500 mg 1.73m\n                    <jats:sup>2<\/jats:sup>\n                    suggest no superiority compared to rituximab in children and young adults with steroid dependent nephrotic syndrome. Ofatumumab given in very high doses (300 mg\/1.73m\n                    <jats:sup>2<\/jats:sup>\n                    followed by five infusion 2,000 mg\/1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ) seems more effective in patients who are not responsive to common therapies. The question of dose remains unresolved and the literature is not concordant on positive effects of high dose ofatumumab in patients with FSGS prior and after renal transplantation. Obinutuzumab may offer some advantages. In the unique study performed in patients with multidrug dependent nephrotic syndrome reporting positive effects, obinutuzumab was associated with the anti-CD38 monoclonal antibody daratumumab proposing the unexplored frontier of combined therapies. Obinutuzumab represent an evolution also in the treatment of autoimmune glomerulonephritis, such as membranous nephrotahy and lupus nephritis. Results of randomized trials, now in progress, are awaited to add new possibilities in those cases that are resistant to other drugs. The aim of the present review is to open a discussion among nephrologists, with the hope to achieve shared approaches in terms of type of antibodies and doses in the different proteinuric renal conditions.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.805697","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:00:35Z","timestamp":1644544835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?"],"prefix":"10.3389","volume":"13","author":[{"given":"Biswanath","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilkish","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Ghiggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","article-title":"The Nephrotic Syndrome in Adults With 'Minimal Change' Glomerular Lesions","volume":"43","author":"Cameron","year":"1974","journal-title":"Q J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)34218-3","article-title":"Nephrotic Syndrome in Childhood. Management and Treatment in Patients With Minimal Change Disease, Mesangial Proliferation, or Focal Glomerulosclerosis","volume":"29","author":"McEnery","year":"1982","journal-title":"Pediatr Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic Nephrotic Syndrome in Children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in Complex With the Therapeutic Monoclonal Antibody Rituximab","volume":"367","author":"Rouge","year":"2020","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in Children With Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08500815","article-title":"Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children","volume":"11","author":"Ravani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw106","article-title":"B Cell-Depleting Therapy With Rituximab or Ofatumumab in Immunoglobulin A Nephropathy or Vasculitis With Nephritis","volume":"10","author":"Lundberg","year":"2017","journal-title":"Clin Kidney J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and Treatment of Glomerular Diseases (Part 2): Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the Rituximab Dose and Maintenance Immunosuppression in Steroid-Dependent\/Frequently-Relapsing Nephrotic Syndrome Have Important Effects on Outcomes","volume":"97","author":"Chan","year":"2020","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04540-4","article-title":"Rituximab for Very Low Dose Steroid-Dependent Nephrotic Syndrome in Children: A Randomized Controlled Study","volume":"35","author":"Ravani","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.6150","article-title":"Rituximab vs Low-Dose Mycophenolate Mofetil In Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial","volume":"175","author":"Ravani","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients With Systemic Lupus Erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for Rituximab-Resistant Nephrotic Syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/332323a0","article-title":"Reshaping Human Antibodies for Therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0133","article-title":"Drug Insight: Rituximab in Renal Disease and Transplantation","volume":"2","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02021.x","article-title":"Rituximab Failed to Improve Nephrotic Syndrome in Renal Transplant Patients With Recurrent Focal Segmental Glomerulosclerosis","volume":"8","author":"Yabu","year":"2008","journal-title":"Am J Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in Steroid-Dependent Idiopathic Nephrotic Syndrome in Childhood\u2013Follow-Up After CD19 Recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015050523","article-title":"B Cell Reconstitution After Rituximab Treatment in Idiopathic Nephrotic Syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-Cell Subpopulations in Patients With Severe Idiopathic Membranous Nephropathy may Predict an Early Response to Rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-018-0748-0","article-title":"Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better","volume":"20","author":"Freeman","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 Monoclonal Antibodies: Reviewing a Revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14534","article-title":"A Phase 1\/2 Trial of Ublituximab, a Novel Anti-CD20 Monoclonal Antibody, in Patients With B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia Previously Exposed to Rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1459560","article-title":"Ublituximab for the Treatment of CD20 Positive B-Cell Malignancies","volume":"27","author":"Babiker","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab Plus Fludarabine and Cyclophosphamide in Relapsed Chronic Lymphocytic Leukemia: Results From the COMPLEMENT 2 Trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-019-0260-2","article-title":"Ofatumumab Maintenance Prolongs Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia: Final Analysis of the PROLONG Study","volume":"9","author":"van Oers","year":"2019","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab Plus Chlorambucil in Patients With CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-613570","article-title":"Obinutuzumab Plus Fludarabine\/Cyclophosphamide or Bendamustine in the Initial Therapy of CLL Patients: The Phase 1b GALTON Trial","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and Safety of New Anti-CD20 Monoclonal Antibodies Versus Rituximab for Induction Therapy of CD20(+) B-Cell Non-Hodgkin Lymphomas: A Systematic Review and Meta-Analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0864","article-title":"Obinutuzumab in Combination With Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-Resistant Non-Hodgkin Lymphoma Cells","volume":"20","author":"Fujimura","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.59","article-title":"Treatment of IgA Nephropathy and Henoch-Schonlein Nephritis","volume":"9","author":"Floege","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-016-3498-y","article-title":"Ofatumumab in Two Pediatric Nephrotic Syndrome Patients Allergic to Rituximab","volume":"32","author":"Vivarelli","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3621-8","article-title":"Ofatumumab for the Treatment of Childhood Nephrotic Syndrome","volume":"32","author":"Wang","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-210208","article-title":"Low-Dose Ofatumumab for Rituximab-Resistant Nephrotic Syndrome","volume":"2015","author":"Bonanni","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","article-title":"Low-Dose Ofatumumab for Multidrug-Resistant Nephrotic Syndrome in Children: A Randomized Placebo-Controlled Trial","volume":"35","author":"Ravani","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-019-04365-w","article-title":"Ofatumumab Rescue Treatment in Post-Transplant Recurrence of Focal Segmental Glomerulosclerosis","volume":"35","author":"Colucci","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13413","article-title":"Ofatumumab in Post-Transplantation Recurrence of Focal Segmental Glomerulosclerosis in a Child","volume":"23","author":"Solomon","year":"2019","journal-title":"Pediatr Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00467-021-05248-9","article-title":"UK Experience of Ofatumumab in Recurrence of Focal Segmental Glomerulosclerosis Post-Kidney Transplant","volume":"37","author":"Reynolds","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14998","article-title":"Successful Management of Recurrent Focal Segmental Glomerulosclerosis","volume":"18","author":"Kienzl-Wagner","year":"2018","journal-title":"Am J Transplant"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04567-7","article-title":"Ofatumumab Treatment for Nephrotic Syndrome Recurrence After Pediatric Renal Transplantation","volume":"35","author":"Bernard","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e232896","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for Multirelapsing Membranous Nephropathy Complicated by Rituximab-Induced Serum-Sickness","volume":"13","author":"Podesta","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-009-1377-5","article-title":"Single Infusion of Rituximab for Persistent Steroid-Dependent Minimal-Change Nephrotic Syndrome After Long-Term Cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021040561","article-title":"Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children With Nephrotic Syndrome: A Superiority Randomized Trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04811-0","article-title":"A Global antiB Cell Strategy Combining Obinutuzumab and Daratumumab in Severe Pediatric Nephrotic Syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/art.41608","article-title":"The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model","volume":"73","author":"Marinov","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13029","article-title":"Ofatumumab-Associated Acute Respiratory Manifestations: Clinical Characteristics and Treatment","volume":"82","author":"Bonanni","year":"2016","journal-title":"Br J Clin Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.805697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:00:38Z","timestamp":1644544838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.805697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.805697"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.805697","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"805697"}}